BRIEF published on 01/19/2026 at 11:50, 5 months 7 days ago Viromed Medical AG Advances with Ex-Vivo Lung Study Viromed Medical AG Cold Plasma Technology Ex-vivo Lung Study Preclinical Research Acceleration Saarland University Collaboration
PRESS RELEASE published on 01/19/2026 at 11:45, 5 months 7 days ago Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval Viromed Medical AG's ex-vivo lung study with Saarland University and MHH is a significant milestone for research & approval, accelerating development processes Research Approval Viromed Medical AG Cold Plasma Technology Ex-vivo Lung Study
BRIEF published on 01/15/2026 at 09:53, 5 months 11 days ago Viromed Medical AG passe aux actions nominatives Actionnaires Bourse Viromed Medical AG Actions Nominatives Technologie Du Plasma Froid
BRIEF published on 01/15/2026 at 09:53, 5 months 11 days ago Viromed Medical AG Transitions to Registered Shares Shareholders Stock Exchange Viromed Medical AG Registered Shares Cold Plasma Technology
PRESS RELEASE published on 01/15/2026 at 09:48, 5 months 11 days ago Viromed Medical AG switches to registered shares Viromed Medical AG converts share capital from bearer shares to registered shares to enhance transparency and direct shareholder communication. Stock trading to commence under new ISIN DE000A40VZN7 Stock Exchange Transparency Viromed Medical AG Registered Shares Bearer Shares
BRIEF published on 01/07/2026 at 14:20, 5 months 19 days ago Viromed AG partage une mise à jour stratégique sur ses avancées en matière de technologies médicales Partenariats Mondiaux Maladies Respiratoires Viromed Medical AG Dispositifs Médicaux Innovants Technologie Du Plasma Froid
BRIEF published on 01/07/2026 at 14:20, 5 months 19 days ago Viromed AG Shares Strategic Update on MedTech Advancements Respiratory Diseases Global Partnerships Innovative Medical Devices Viromed Medical AG Cold Plasma Technology
PRESS RELEASE published on 01/07/2026 at 14:15, 5 months 19 days ago Viromed AG: Strategic Update on Operational Focus and Value Creation Viromed Medical AG provides strategic update on operational focus and value creation in the field of cold plasma technology and medical devices development Medical Devices Value Creation Viromed Medical AG Cold Plasma Technology Operational Focus
BRIEF published on 11/28/2025 at 17:33, 6 months 28 days ago Viromed Medical AG and HELLMUT RUCK GmbH Enter Exclusive Distribution Agreement Distribution Agreement Medical Technologies Viromed Medical AG HELLMUT RUCK GmbH Plasma Devices
BRIEF published on 11/28/2025 at 17:33, 6 months 28 days ago Viromed Medical AG et HELLMUT RUCK GmbH concluent un accord de distribution exclusive Accord De Distribution Viromed Medical AG Technologies Médicales HELLMUT RUCK GmbH Dispositifs Plasma
Published on 06/26/2026 at 22:15, 7 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/26/2026 at 14:05, 8 hours 17 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 8 hours 22 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 9 hours 22 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 19:50, 2 hours 32 minutes ago Name Change Completed for C Capital's Swiss Listed Entity, Ticker Symbol CCAP Goes Live
Published on 06/26/2026 at 19:10, 3 hours 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/26/2026 at 18:04, 4 hours 18 minutes ago Turkiye Garanti Bankasi A.S.: Bond, subordinated debts, that can be included in the equity calculation debt instrument issuance CMB Application
Published on 06/26/2026 at 18:00, 4 hours 22 minutes ago PSP Swiss Property has sold the Richtipark in Wallisellen. The EBITDA guidance for the 2026 financial year has been increased.
Published on 06/26/2026 at 18:00, 4 hours 22 minutes ago VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M
